Cargando…

Daily Management of Patients on Multikinase Inhibitors’ Treatment

In a minority of differentiated thyroid cancer (TC) cases and in a large percentage of poorly differentiated TCs (PDTCs) and anaplastic TCs (ATCs), the prognosis is poor due to the lack of response to conventional treatments. In the last two decades, multikinase inhibitor (MKI) compounds have been d...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Carla, De Leo, Simone, Trevisan, Matteo, Giancola, Noemi, Scaltrito, Anna, Fugazzola, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290676/
https://www.ncbi.nlm.nih.gov/pubmed/35860593
http://dx.doi.org/10.3389/fonc.2022.903532
_version_ 1784748959061770240
author Colombo, Carla
De Leo, Simone
Trevisan, Matteo
Giancola, Noemi
Scaltrito, Anna
Fugazzola, Laura
author_facet Colombo, Carla
De Leo, Simone
Trevisan, Matteo
Giancola, Noemi
Scaltrito, Anna
Fugazzola, Laura
author_sort Colombo, Carla
collection PubMed
description In a minority of differentiated thyroid cancer (TC) cases and in a large percentage of poorly differentiated TCs (PDTCs) and anaplastic TCs (ATCs), the prognosis is poor due to the lack of response to conventional treatments. In the last two decades, multikinase inhibitor (MKI) compounds have been developed and demonstrated to be very effective in these aggressive cases. Besides the great efficacy, several adverse events (AEs) have been reported in virtually all patients treated with MKIs, largely overlapping between different compounds and including hypertension, diarrhea, anorexia, decreased weight, fatigue, and proteinuria. Most grade 3–4 adverse reactions occur during the first 6 months of treatment and require dosage reduction and/or drug discontinuation. Due to severity of the AEs related to the treatment with MKIs, a multidisciplinary team is definitely required for the daily management of these patients, for the evaluation of the disease status, and the psychophysical condition. Moreover, it is crucial that the patients could have a facilitated access to reach either specialist doctors or nurses who must have been trained to follow them for their individual clinical complications. The follow-up visits should take place at monthly intervals until the sixth month and then every 1–2 months until the completion of the first year of treatment. The flow chart followed at our tertiary center is reported in the present review as a real-life-based example for the follow-up of patients with advanced TC on MKI treatment.
format Online
Article
Text
id pubmed-9290676
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92906762022-07-19 Daily Management of Patients on Multikinase Inhibitors’ Treatment Colombo, Carla De Leo, Simone Trevisan, Matteo Giancola, Noemi Scaltrito, Anna Fugazzola, Laura Front Oncol Oncology In a minority of differentiated thyroid cancer (TC) cases and in a large percentage of poorly differentiated TCs (PDTCs) and anaplastic TCs (ATCs), the prognosis is poor due to the lack of response to conventional treatments. In the last two decades, multikinase inhibitor (MKI) compounds have been developed and demonstrated to be very effective in these aggressive cases. Besides the great efficacy, several adverse events (AEs) have been reported in virtually all patients treated with MKIs, largely overlapping between different compounds and including hypertension, diarrhea, anorexia, decreased weight, fatigue, and proteinuria. Most grade 3–4 adverse reactions occur during the first 6 months of treatment and require dosage reduction and/or drug discontinuation. Due to severity of the AEs related to the treatment with MKIs, a multidisciplinary team is definitely required for the daily management of these patients, for the evaluation of the disease status, and the psychophysical condition. Moreover, it is crucial that the patients could have a facilitated access to reach either specialist doctors or nurses who must have been trained to follow them for their individual clinical complications. The follow-up visits should take place at monthly intervals until the sixth month and then every 1–2 months until the completion of the first year of treatment. The flow chart followed at our tertiary center is reported in the present review as a real-life-based example for the follow-up of patients with advanced TC on MKI treatment. Frontiers Media S.A. 2022-07-04 /pmc/articles/PMC9290676/ /pubmed/35860593 http://dx.doi.org/10.3389/fonc.2022.903532 Text en Copyright © 2022 Colombo, De Leo, Trevisan, Giancola, Scaltrito and Fugazzola https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Colombo, Carla
De Leo, Simone
Trevisan, Matteo
Giancola, Noemi
Scaltrito, Anna
Fugazzola, Laura
Daily Management of Patients on Multikinase Inhibitors’ Treatment
title Daily Management of Patients on Multikinase Inhibitors’ Treatment
title_full Daily Management of Patients on Multikinase Inhibitors’ Treatment
title_fullStr Daily Management of Patients on Multikinase Inhibitors’ Treatment
title_full_unstemmed Daily Management of Patients on Multikinase Inhibitors’ Treatment
title_short Daily Management of Patients on Multikinase Inhibitors’ Treatment
title_sort daily management of patients on multikinase inhibitors’ treatment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290676/
https://www.ncbi.nlm.nih.gov/pubmed/35860593
http://dx.doi.org/10.3389/fonc.2022.903532
work_keys_str_mv AT colombocarla dailymanagementofpatientsonmultikinaseinhibitorstreatment
AT deleosimone dailymanagementofpatientsonmultikinaseinhibitorstreatment
AT trevisanmatteo dailymanagementofpatientsonmultikinaseinhibitorstreatment
AT giancolanoemi dailymanagementofpatientsonmultikinaseinhibitorstreatment
AT scaltritoanna dailymanagementofpatientsonmultikinaseinhibitorstreatment
AT fugazzolalaura dailymanagementofpatientsonmultikinaseinhibitorstreatment